Wall Street brokerages predict that Bayer AG (NASDAQ:BAYRY) will report $2.06 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Bayer AG’s earnings. Bayer AG reported earnings per share of $2.34 in the same quarter last year, which would suggest a negative year over year growth rate of 12%. The business is scheduled to report its next quarterly earnings results on Wednesday, July 26th.
On average, analysts expect that Bayer AG will report full year earnings of $8.75 per share for the current year, with EPS estimates ranging from $8.69 to $8.81. For the next year, analysts forecast that the firm will post earnings of $9.41 per share, with EPS estimates ranging from $9.35 to $9.48. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Bayer AG.
Bayer AG (NASDAQ:BAYRY) last released its earnings results on Thursday, April 27th. The company reported $2.80 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.40 by $0.40. The company had revenue of $14.11 billion during the quarter, compared to the consensus estimate of $13.65 billion.
Several equities analysts have recently commented on the stock. Zacks Investment Research cut shares of Bayer AG from a “hold” rating to a “sell” rating in a research report on Monday, April 17th. Sanford C. Bernstein restated an “outperform” rating on shares of Bayer AG in a research report on Friday, February 24th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. Bayer AG presently has a consensus rating of “Buy” and an average price target of $111.00.
Bayer AG (NASDAQ:BAYRY) traded up 1.91% on Tuesday, reaching $130.07. 268,469 shares of the company traded hands. The firm has a market cap of $113.34 billion and a P/E ratio of 19.72. The stock has a 50-day moving average price of $118.42 and a 200-day moving average price of $109.23. Bayer AG has a 52-week low of $91.53 and a 52-week high of $130.35.
Bayer AG Company Profile
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with our FREE daily email newsletter.